A New Treatment for Ph-positive ALL Outperformed Chemotherapy

Removing intensive systemic chemotherapy from the treatment of an aggressive blood cancer might seem like a dangerous compromise. Yet a new treatment for Ph-positive ALL has produced substantially better results than a conventional chemotherapy-based regimen.

At two years, estimated event-free survival was 86% among patients receiving the new combination, compared with 67% in the control group. The 19-percentage-point difference was statistically significant.

The findings, published in the New England Journal of Medicine on October 14, 2026, come from GIMEMA ALL2820, a randomized phase 3 trial involving 236 adults.

The advantage was not simply a consequence of removing chemotherapy. The experimental regimen combined two drugs that attack leukemia through very different biological mechanisms.

A leukemia driven by a genetic rearrangement

The trial focused on Philadelphia chromosome-positive acute lymphoblastic leukemia, commonly called Ph-positive ALL.

This particular form of blood cancer is driven by a chromosomal rearrangement that creates the BCR::ABL1 fusion gene.

The resulting protein behaves like a growth-promoting switch that is permanently turned on. Instead of responding to the normal signals governing cell division, leukemic cells receive a persistent instruction to proliferate.

Drugs that inhibit BCR::ABL1 have already transformed the outlook for patients with Ph-positive ALL. Nevertheless, treatment has traditionally involved combining these targeted agents with chemotherapy. Some patients have also required hematopoietic stem-cell transplantation.

The investigators wanted to know whether a more potent BCR::ABL1 inhibitor, paired with an immune-based therapy, could control the leukemia more effectively without relying on intensive systemic chemotherapy.

Two drugs, two ways to attack leukemia

The experimental strategy combined ponatinib and blinatumomab.

Ponatinib inhibits the abnormal BCR::ABL1 protein, disrupting a central signaling pathway that leukemia cells depend on for survival and proliferation.

Blinatumomab works by recruiting the patient's own immune system.

It is a bispecific antibody that recognizes two different proteins: CD19, expressed on malignant B cells, and CD3, found on T lymphocytes.

By binding to both cells, blinatumomab brings the immune cell into close contact with its target and helps trigger an attack.

The combination therefore tackles the cancer from two directions. One drug interferes with a critical oncogenic signal, while the other directs T cells toward leukemia cells.

To test the approach, investigators randomly assigned 236 patients to two groups.

The experimental group included 158 patients treated with ponatinib plus blinatumomab. The control group included 78 patients receiving imatinib, another BCR::ABL1 inhibitor, together with conventional chemotherapy.

The median patient age was 55 years, and the median follow-up was 23.7 months.

Differences between the groups emerged early.

Following induction therapy, 94% of patients in the experimental group achieved a complete hematologic response, compared with 79% in the control group.

After consolidation treatment, a molecular response was observed in 71% and 49% of patients, respectively.

These molecular measurements matter because a patient can appear to be in remission while a very small population of malignant cells remains.

This is known as measurable residual disease, or MRD. Such cells may eventually expand and cause the leukemia to return.

Survival without detectable measurable residual disease was also higher in the experimental group: 68% versus 42%.

The estimated cumulative incidence of relapse was 5%, compared with 13% among patients receiving imatinib and chemotherapy.

And for the trial's primary endpoint, estimated event-free survival at 24 months was 86% versus 67%, with a P value below 0.001.

These results provide strong evidence that the experimental regimen controlled the disease more effectively than the comparator over the period studied.

What chemotherapy-free actually means

There is an important distinction behind the term chemotherapy-free.

The experimental regimen did not use conventional intensive systemic chemotherapy as its main antileukemic treatment.

Patients still received additional care, including prophylaxis against leukemia involving the central nervous system.

The study protocol included 15 lumbar punctures for the administration of intrathecal treatment, with additional administrations for patients who had central nervous system involvement at diagnosis.

This treatment included chemotherapy agents such as methotrexate and cytarabine, delivered directly into the cerebrospinal fluid.

Consequently, chemotherapy-free in this context means avoiding the conventional systemic chemotherapy backbone. It does not mean that every cytotoxic drug was eliminated from the treatment protocol.

Nor does it mean that the experimental drugs are harmless.

Ponatinib carries risks of serious vascular complications, including thrombotic events. Blinatumomab can cause cytokine-release syndrome and neurological toxicity.

Replacing conventional chemotherapy changes the toxicity profile, but it does not eliminate the need for careful monitoring and specialized medical care.

Could some patients avoid transplantation?

The trial also raises questions about the future role of stem-cell transplantation.

At the time of reporting, only 19% of patients in the experimental group had undergone transplantation after their first complete hematologic remission.

Transplant decisions were guided by biological risk factors, including measurable residual disease and specific genetic features.

This suggests that a substantial proportion of patients may be able to achieve disease control without proceeding immediately to transplantation.

However, the trial did not directly randomize patients to transplantation versus no transplantation. It cannot establish that transplantation is unnecessary for all patients receiving the new regimen.

The distinction between disease control and cure is equally important.

An 86% two-year event-free survival rate does not mean that 86% of patients have been permanently cured. It represents the estimated proportion remaining free of the events defined by the trial's endpoint at that time.

Overall survival was 90% in the experimental group and 85% in the control group. A statistically established overall survival advantage was not demonstrated in the published analysis.

The interpretation is complicated by the trial's crossover design.

Patients in the control group whose measurable residual disease persisted or reappeared were allowed to switch to ponatinib plus blinatumomab.

Thirty-one patients crossed over, and 20 subsequently achieved a molecular response.

This feature could affect comparisons of overall survival between the two original treatment groups.

There is another limitation to interpreting the results: both the targeted inhibitor and the chemotherapy component differed between the regimens.

The study therefore establishes the superiority of one complete treatment strategy over another. It cannot determine how much of the benefit came specifically from avoiding systemic chemotherapy, using ponatinib instead of imatinib, or adding blinatumomab.

The median follow-up of less than two years also leaves important questions about long-term durability, late toxicity, and the optimal duration of treatment.

Even with these qualifications, the findings represent a consequential advance for Philadelphia chromosome-positive ALL.

Earlier nonrandomized studies had suggested that chemotherapy-free targeted and immune-based regimens could be highly effective. GIMEMA ALL2820 now provides randomized phase 3 evidence that ponatinib plus blinatumomab can outperform imatinib plus chemotherapy.

For this genetically defined leukemia, suppressing its central growth signal while recruiting T cells against malignant cells proved more effective than the chemotherapy-containing strategy against which it was tested.